Insulin Lispro
- Generic Name
- Insulin Lispro
- Brand Names
- Admelog, Humalog, Humalog Mix, Humalog kwikpen, Liprolog, Lyumjev, Insulin lispro Sanofi, Lyumjev (previously Liumjev)
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 133107-64-9
- Unique Ingredient Identifier
- GFX7QIS1II
- Background
Insulin lispro is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin is release...
- Indication
本品尤其适用于下列情况：
1.经常发生低血糖的1型糖尿病者，使用本品可减少低血糖的发生率；
2.生活不规律，外出活动较多的用胰岛素治疗的糖尿病患者，本品快速、短效的特点有助于及时调整胰岛素的用量。
- Associated Conditions
- Diabetes Mellitus, Diabetic Ketoacidosis, Gestational Diabetes Mellitus (GDM)
- Associated Therapies
- -
A Study in Participants With Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2011-11-10
- Last Posted Date
- 2018-04-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1369
- Registration Number
- NCT01468987
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Guildford, Surrey, United Kingdom
A Study in Participants With Type I Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2011-10-18
- Last Posted Date
- 2018-04-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1114
- Registration Number
- NCT01454284
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oxford, United Kingdom
A Study in Adults With Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2011-08-22
- Last Posted Date
- 2014-10-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 536
- Registration Number
- NCT01421147
- Locations
- 🇷🇴
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Timisoara, Romania
Pharmacokinetic and Pharmacodynamic Properties of BIOD-105 and BIOD-107 Compared to Humalog® in Subjects With Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2011-04-13
- Last Posted Date
- 2013-07-26
- Lead Sponsor
- Biodel
- Target Recruit Count
- 13
- Registration Number
- NCT01334151
- Locations
- 🇺🇸
Profil Institute for Clinical Research, Inc. (PICR), Chula Vista, California, United States
A Study Evaluating the Bioequivalence of VIAject®7 Compared to VIAject®25 and Comparing the Pharmacokinetic and Pharmacodynamic Properties of VIAject®7 to Insulin Lispro in Subjects With Type 1 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2010-11-05
- Last Posted Date
- 2015-07-29
- Lead Sponsor
- Biodel
- Target Recruit Count
- 43
- Registration Number
- NCT01235039
- Locations
- 🇩🇪
Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany
Study of Insulin Lispro in Participants With Inadequately Controlled Type 2 Diabetes
- First Posted Date
- 2010-10-07
- Last Posted Date
- 2014-04-23
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1117
- Registration Number
- NCT01215955
- Locations
- 🇿🇦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Somerset West, South Africa
PK/PD Study of Intranasal Insulin in Type I Diabetes
- First Posted Date
- 2010-09-14
- Last Posted Date
- 2011-06-17
- Lead Sponsor
- Hompesch, Marcus, M.D.
- Target Recruit Count
- 20
- Registration Number
- NCT01201278
- Locations
- 🇺🇸
Profil Institute for Clinical Research, Chula Vista, California, United States
Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patients With Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2010-09-02
- Last Posted Date
- 2014-08-20
- Lead Sponsor
- Halozyme Therapeutics
- Target Recruit Count
- 132
- Registration Number
- NCT01194258
- Locations
- 🇺🇸
Mercury Street Medical, Butte, Montana, United States
🇺🇸UT Southwestern Medical Center at Dallas, Dallas, Texas, United States
🇺🇸John Muir Physician Network Clinical Research Center, Concord, California, United States
Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2010-09-02
- Last Posted Date
- 2019-02-26
- Lead Sponsor
- Halozyme Therapeutics
- Target Recruit Count
- 135
- Registration Number
- NCT01194245
- Locations
- 🇺🇸
Mercury Street Medical, Butte, Montana, United States
🇺🇸Mid-America Diabetes Associates, Wichita, Kansas, United States
🇺🇸Rocky Mountain Diabetes and Osteoporosis Center, Idaho Falls, Idaho, United States
A Study in Participants With Type 2 Diabetes Mellitus (AWARD-4)
- Conditions
- Interventions
- First Posted Date
- 2010-08-30
- Last Posted Date
- 2014-10-08
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 884
- Registration Number
- NCT01191268
- Locations
- 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Yong Kang City, Taiwan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.